Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ignyta Announces Acquisition of Actagene Oncology and Entry into Oncology Personalized Medicine

Published: Tuesday, May 21, 2013
Last Updated: Tuesday, May 21, 2013
Bookmark and Share
Company adds world class drug discovery and development veterans to management and advisory team.

Ignyta, Inc. announced that it has acquired Actagene Oncology, Inc., effective May 20, 2013. Actagene was a San Diego based privately held biotechnology company founded in February 2013 that was developing personalized medicines for high unmet need cancer indications, based on cancer genome mining and sequencing.

With the acquisition, Ignyta has evolved its business strategy from a sole focus on molecular diagnostics for autoimmune disease to an integrated “Rx/Dx” focus on drug and biomarker discovery and development for cancer and immunology. Patrick O’Connor, Ph.D., CEO of Actagene Oncology, has joined Ignyta as Chief Scientific Officer and SVP, Head of Research. His contributions to the field of oncology include over 100 publications and patents and over 20 compounds brought into development, including the recently approved anticancer drugs Xalkori (Crizotinib) and Inlyta (Axitinib), discovered at Pfizer where Dr. O’Connor served as the Global Research Therapeutic Area Head for Oncology.

Other additions to Ignyta’s management team include Jean-Michel Vernier, Ph.D., who formerly led chemistry groups at Ardea Biosciences, Valeant Pharmaceuticals and Merck Research Laboratories, to serve as VP, Medicinal Chemistry; Paul Pearson, Ph.D., former Global Head and VP, Pharmacokinetics and Drug Metabolism at Amgen, to head PK, Drug Metabolism & Safety; and Dave Matthews, Ph.D., the scientific founder of Agouron Pharmaceuticals, to head Crystallography at Ignyta. James Bristol, Ph.D., former Worldwide Head of Pfizer Discovery and Former Head of Discovery and Chemistry at Warner-Lambert/Parke Davis, at which site Lipitor was discovered by his Chemistry team, joined Ignyta’s Scientific Advisory Board.

“The Actagene acquisition provides Ignyta with a strategic entry into oncology personalized medicine, an area with high unmet medical need and opportunities to give patients customized treatment options that leverage Ignyta’s biomarker discovery capabilities. Ignyta also gains the addition of Patrick O’Connor and the rest of his world class oncology drug hunter team that has collectively discovered and developed 10 approved drugs representing over $5 billion in 2012 sales,” said Jonathan Lim, M.D., chairman and CEO of Ignyta. “Actagene’s R&D team complements Ignyta’s existing team, platform and capabilities, such as whole genome methylation analysis, next generation sequencing, Methylome™ database, and bioinformatics expertise. This transaction reshapes us into a seamless Rx/Dx company pursuing a significant growth area of patient stratification and targeted drug discovery and development for cancer patients.”

Actagene Oncology applies its proprietary Oncolome™ database and technologies such as synthetic lethal screening, x-ray crystallography and structure-based drug design to develop new chemical entities against genetic targets that are enriched in certain cancer populations.

“I am excited for the Actagene team to join forces with the Ignyta team, several of whom I had the pleasure to previously work with when I was at Halozyme,” said Dr. O’Connor. “Actagene’s Oncolome platform will combine synergistically with Ignyta’s Methylome platform to provide both genetic and epigenetic insights from patient tumor samples to identify and pursue personalized medicines against activated genes in cancer. The driving scientific focus for our new company will be the discovery and development of revolutionary new drugs targeting activated genes driving cancer growth and evasion of the immune system.”

In addition to its new focus on targeted therapeutic discovery for cancer, Ignyta will continue to advance its companion diagnostic initiatives to generate epigenetic signatures that are predictive of treatment response for specific drug mechanisms within both autoimmune disease and cancer.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Light of Fireflies for Medical Diagnostics
EPFL scientists have exploited the light of fireflies in a new method that detects biological molecules without the need for complex devices and high costs.
Vital Protein in Healthy Fertilization Process Identified
Researchers at the National Institutes of Health have discovered a protein that plays a vital role in healthy egg-sperm union in mice.
Teeth Reveal Lifetime Exposures to Metals, Toxins
Researchers have identified dental biomarkers to reveal links between early iron exposure and late life brain diseases.
Simple Technology Makes CRISPR Gene Editing Cheaper
University of California, Berkeley, researchers have discovered a much cheaper and easier way to target a hot new gene editing tool, CRISPR-Cas9, to cut or label DNA.
Could a simple saliva test detect Alzheimer's?
Researchers have presented findings suggesting that a simple, non-invasive diagnostic for Alzheimer's could be within reach.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!